Botulinum toxin type A (BTX-A) represent the gold standard therapy for focal dystonia and related hyperkinetic movement disorders. The main advantages of this method are low rate of complications, reversibility and efficacy in reducing spastic hypertonia or abnormal movements. The treatment is safe but it needs to be repeated periodically and some patients do not obtain effective control of the symptoms due to the onset of secondary immune resistance. For this reason we have selected 45 cases already in treatment with botulinum toxin that have been switched to incobotulinumtoxinA. At a median follow up of 8 months the greatest part of the patients, twenty-six (57.7%) remained clinically unchanged; fourteen (31.1%) had a significant clinical improvement and five (11.1%) worsened. We did not observe any general or injection site complications.

Focal dystonia and botulinum toxin: Our experience with incobotulinumtoxina

TACCONI, Leonello;Mazzon G.;Manganotti P.
2019-01-01

Abstract

Botulinum toxin type A (BTX-A) represent the gold standard therapy for focal dystonia and related hyperkinetic movement disorders. The main advantages of this method are low rate of complications, reversibility and efficacy in reducing spastic hypertonia or abnormal movements. The treatment is safe but it needs to be repeated periodically and some patients do not obtain effective control of the symptoms due to the onset of secondary immune resistance. For this reason we have selected 45 cases already in treatment with botulinum toxin that have been switched to incobotulinumtoxinA. At a median follow up of 8 months the greatest part of the patients, twenty-six (57.7%) remained clinically unchanged; fourteen (31.1%) had a significant clinical improvement and five (11.1%) worsened. We did not observe any general or injection site complications.
2019
Pubblicato
https://www.neuroquantology.com/article.php?id=1376
File in questo prodotto:
File Dimensione Formato  
Focal dystonia.pdf

Accesso chiuso

Tipologia: Documento in Versione Editoriale
Licenza: Digital Rights Management non definito
Dimensione 592.22 kB
Formato Adobe PDF
592.22 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2954749
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact